Advertisement
Research Article| Volume 29, ISSUE 4, 104628, April 2020

Why Physicians Prescribe Prophylactic Seizure Medications after Intracerebral Hemorrhage: An Adaptive Conjoint Analysis

      Abstract

      Background: Seizures are a morbid complication of intracerebral hemorrhage (ICH) and increase the risk for herniation, status epilepticus, and worse patient outcomes. Prophylactic levetiracetam is administered to approximately 40% of patients with ICH. It is unclear which patients are consciously selected for treatment by physicians. We sought to determine how patients are selected for treatment with prophylactic levetiracetam after ICH. Methods: We administered an adaptive conjoint analysis using decision making software to an NIH Stroke Trials Network Working Group. The adaptive conjoint analysis determines the most influential attributes for making a decision in an iterative, algorithm-driven process. We asked respondents which would most influence a decision to administer prophylactic levetiracetam. The attributes and their levels were taken from published phenotypes associated with prophylactic seizure medications and the likelihood of seizures after ICH: hematoma location (lobar or basal ganglia), hematoma volume (<=10 mL or >10 mL), level of consciousness (Glasgow Coma Scale 5-12 or Glasgow Coma Scale 13-15), age (<65 or ≥65 years), and race (White or Caucasian or Black/African American). The algorithm terminated when the attributes were ranked from most to least influential. Results: The study sample included 27 respondents who completed the adaptive conjoint analysis out of 42 who responded to the survey with a mean age of 43.4 ± 9.4 years. The attribute with the greatest weight was hematoma location (30%), followed by reduced level of consciousness (24%), hematoma volume (19%), race (14%), and age (13%). Ranks of attributes were different (P < .001). Conclusions: The decision to administer prophylactic levetiracetam to patients with ICH is driven by lobar hematoma location and depressed level of consciousness. Future research on prophylactic seizure medication could focus on patients most likely to receive it.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Stroke and Cerebrovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Vespa P.M.
        • O'Phelan K.
        • Shah M.
        • et al.
        Acute seizures after intracerebral hemorrhage: a factor in progressive midline shift and outcome.
        Neurology. 2003; 60: 1441-1446
        • Broderick J.
        • Connolly S.
        • Feldmann E.
        • et al.
        Guidelines for the management of spontaneous intracerebral hemorrhage in adults. 2007 Update.
        Stroke. 2007; 38: 2001-2023
        • Naidech A.M.
        • Beaumont J.
        • Prabhakaran S.
        • Kho A.N.
        • Holl J.L.
        Evolving use of seizure medications after intracerebralhemorrhage: a multi-center study.
        Neurology. 2017; 88: 52-56
        • Naidech A.M.
        • Garg R.K.
        • Liebling S.
        • et al.
        Anticonvulsant use and outcomes after intracerebral hemorrhage.
        Stroke. 2009; 40: 3810-3815
        • Messe S.R.
        • Sansing L.H.
        • Cucchiara B.L.
        • et al.
        Prophylactic antiepileptic drug use is associated with poor outcome following ICH.
        Neurocrit Care. 2009; 11: 38-44
        • Sheth K.N.
        • Martini S.R.
        • Moomaw C.J.
        • et al.
        Prophylactic antiepileptic drug use and outcome in the ethnic/racial variations of intracerebral hemorrhage Study.
        Stroke. 2015; 46: 3532-3535
        • Haapaniemi E.
        • Strbian D.
        • Rossi C.
        • et al.
        The CAVE score for predicting late seizures after intracerebral hemorrhage.
        Stroke. 2014; 45: 1971-1976
        • Hemphill 3rd, J.C.
        • Greenberg S.M.
        • Anderson C.S.
        • et al.
        Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.
        Stroke. 2015; 46: 2032-2060
        • Naidech A.M.
        • Beaumont J.
        • Muldoon K.
        • et al.
        Prophylactic seizure medication and health-related quality of life after intracerebral hemorrhage.
        Crit Care Med. 2018; 46: 1480-1485
        • Rosenthal L.J.
        • Francis B.A.
        • Beaumont J.L.
        • et al.
        Agitation, delirium, and cognitive outcomes in intracerebral hemorrhage.
        Psychosomatics. 2017; 58: 19-27
        • Hemphill J.
        • Bonovich D.
        • Besmertis L.
        • et al.
        The ICH Score: a simple, reliable grading scale for intracerebral hemorrhage.
        Stroke. 2001; 32: 891-897
        • Naidech A.M.
        • Toledo P.
        • Prabhakaran S.
        • et al.
        Disparities in the use of seizure medications after intracerebral hemorrhage.
        Stroke. 2017; 48: 802-804
        • Liberman A.L.
        • Pinto D.
        • Rostanski S.K.
        • et al.
        Clinical decision-making for thrombolysis of acute minor stroke using adaptive conjoint analysis.
        Neurohospitalist. 2019; 9: 9-14
        • Hansen P.
        • Ombler F.
        A new method for scoring additive multiattribute value models using pairwise rankings of alternative.
        J Multi-Criteria Decis Anal. 2008; 15: e107
        • Struck A.F.
        • Ustun B.
        • Ruiz A.R.
        • et al.
        Association of an electroencephalography-based risk score with seizure probability in hospitalized patients.
        JAMA Neurol. 2017; 74: 1419-1424